Founded in Freising (near Munich), co-located in Boston (USA), NASDAQ-listed Pieris joins forces in immuno-oncology drug development with Servier Pharma (France).
Please enter a searchword.
On November 29 and 30, 230 experts from all over Europe participated in the 6th Munich Biomarker Conference in Munich. The international conference on personalized medicine was organized by BioM, the network agency of Bavaria’s biotechnology industry. Interdisciplinary exchange and dialogue between researchers, physicians, and industry had been...
Immuno-oncology startup iOmx Therapeutics has raised 40 million Euro in its first round of financing.
"We are delighted to collaborate with bluebird bio, a leader in the field of cell and gene therapy, including cancer immunotherapy," said Dolores J. Schendel.
The Munich-based firm also starts to gain a foothold in the American market by setting up a new company in the US (Boston).
Munich Biotech Cluster and lessons learned in 20 years of support for entrepreneurship in biopharma.
On April 19th, the Center for Molecular Biosystems (BioSysM) of the Ludwig-Maximilians-Universität (LMU) celebrated its official opening. The new building on the High Tech Campus Martinsried-Großhadern...